Trial · NCT07912996
Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes
NCT07912996, Phase 2, Not yet recruiting, Gilead Sciences
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes. Trials, record NCT07912996. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912996
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes
- NCT number
- NCT07912996
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 300 participants, estimated
- Lead sponsor
- Gilead Sciences
- Conditions
- HSV-2 Infection
- Interventions
- GS-1179, GS-1179 PTM, Valacyclovir, Valacyclovir PTM
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Experiencing Adverse Events (AEs) | Enrollment up to 92 days | |
| Primary | Percentage of Participants Experiencing Premature Study-Dug Discontinuation due to AEs | Enrollment up to 92 days | |
| Primary | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | First dose date up to 92 days | |
| Primary | Herpes Simplex Virus Type 2 (HSV-2) Shedding Rate During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | Proportion of Participants Free of Genital Herpes Recurrences at Day 92 | Day 92 | |
| Secondary | Proportion of Participants Free of Genital Herpes Recurrences at Day 120 | Day 120 | |
| Secondary | Genital Herpes Lesion Rate During the Treatment Period | Up to 92 days | |
| Secondary | Genital Herpes Lesion Duration During the Treatment Period | Up to 92 days | |
| Secondary | Virologically Confirmed Genital Herpes Lesion Rate During the Treatment Period | Up to 92 days | |
| Secondary | Virologically Confirmed Genital Herpes Lesion Duration During the Treatment Period | Up to 92 days |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912996
GET https://conductscience.org/api/trials/v1/NCT07912996/registered?page=2